Status:
COMPLETED
A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs
Lead Sponsor:
Kocaeli University
Conditions:
Carbapenem Resistant Enterobacteriaceae Infection
Artificial Intelligence
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study to predict carbapenem resistant Klebsiella spp. earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence. Patients with bloodstr...
Detailed Description
Antimicrobial resistance is a globally increasing threat and has serious consequences on both public health and the economy. In an infection that may develop with a resistant microorganism, therapeuti...
Eligibility Criteria
Inclusion
- Patients monitored in our third-level intensive care unit between June 2017 and June 2023 will be evaluated retrospectively. Patients with pneumonia and bloodstream infection developed with Klebsiella spp. will be included in the study.
Exclusion
- Patients under the age of 18 have not been included in the study.
- Infections outside of the respiratory tract and bloodstream have not been included in the study.
- Patients with respiratory tract colonization and without active inflammation have also not been included.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
289 Patients enrolled
Trial Details
Trial ID
NCT05985057
Start Date
December 1 2023
End Date
June 30 2024
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kocaeli University
Kocaeli, Turkey (Türkiye)